Retatrutide — the triple-agonist peptide, explained
Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly that simultaneously activates three receptors: GLP-1, GIP, and glucagon. It is the first compound in clinical research to combine all three incretin-family arms in a single molecule, and it sits one generation beyond tirzepatide (the dual GLP-1/GIP agonist Lilly currently markets as Mounjaro and Zepbound). This primer walks through the pharmacology, the three receptor arms, how retatrutide differs from semaglutide and tirzepatide, the published research record as of 2025, and what serious researchers should know before working with it.
Why triple agonism matters. The incretin system is a feedback loop between the gut, the pancreas, and the brain. GLP-1 (glucagon-like peptide-1) is secreted after eating and signals fullness, slows gastric emptying, and promotes insulin release. GIP (glucose-dependent insulinotropic polypeptide) operates on a parallel track — it amplifies insulin response to glucose and has emerging effects on adipose tissue metabolism. Glucagon, traditionally framed as "the opposite of insulin," has a second role beyond glucose regulation: it directly increases energy expenditure by promoting lipolysis and hepatic fatty acid oxidation. Mono-agonists like semaglutide capture only the GLP-1 arm. Dual agonists like tirzepatide capture GLP-1 + GIP and roughly double the receptor engagement. Retatrutide adds glucagon — which in preclinical models converts the molecule from an appetite-suppression agent into an appetite-suppression + energy-expenditure agent.
The three receptor arms, in detail. The GLP-1 receptor (GLP-1R) is a class B G-protein coupled receptor expressed on pancreatic β-cells, vagal afferents, and multiple brain regions including the arcuate nucleus. Activation triggers insulin secretion in a glucose-dependent manner (so hypoglycemia risk is low), delays gastric emptying, and produces centrally-mediated satiety. The GIP receptor (GIPR) is also a class B GPCR expressed on pancreatic β-cells and, importantly, on adipocytes. GIPR agonism in isolation had disappointing early clinical history — it was considered "insulinotropic but nothing else" — until tirzepatide's dual-agonism data surprised the field by suggesting GIPR contributes meaningfully to weight outcomes when co-activated with GLP-1R. The glucagon receptor (GCGR) is expressed primarily on hepatocytes and adipocytes. Chronic GCGR activation historically raises concerns about hyperglycemia, which is why glucagon agonism had been explored mostly in combination with GLP-1 (the GLP-1 arm counteracts the glucose-raising effect). Retatrutide's sequence is engineered to give a specific potency ratio across the three receptors, balancing metabolic benefit against the glycemic risk profile.
Mechanistic novelty. In preclinical models (mouse DIO, non-human primate), retatrutide produces weight changes that exceed what either semaglutide or tirzepatide achieve at equipotent GLP-1R engagement. The mechanistic story is that adding GCGR activation increases resting energy expenditure by 5–15% in controlled studies, while the GLP-1R arm continues to suppress appetite. The net result is an additive effect on energy balance — reduced intake and increased expenditure — which is the theoretical maximum of what a single pharmacological agent can achieve on body-composition endpoints.
Comparative context (research-only, not therapeutic recommendation). Semaglutide is a GLP-1 mono-agonist; the weight-related effect in published trials scales approximately 1× relative to the GLP-1 arm alone. Tirzepatide is a GLP-1/GIP dual agonist; published phase III data show approximately 1.4× the weight-related effect of semaglutide at matched doses, attributable to the GIPR contribution. Retatrutide is a GLP-1/GIP/GCGR triple agonist; published phase II data suggest approximately 1.7–2.0× the weight-related effect of semaglutide in early reads, with longer-duration phase III readouts ongoing. Exact ratios depend on dose, titration schedule, and population, and should not be interpreted as clinical claims.
Published research — primary sources. The foundational phase I/II data on retatrutide is Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526 (doi: 10.1056/NEJMoa2301972). This is the paper serious research readers should start with — it defines the dose-response curve for retatrutide at 1, 4, 8, and 12 mg weekly and establishes the pharmacokinetic profile. The second key paper is Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529–544 (doi: 10.1016/S0140-6736(23)01053-X), which provides the parallel dataset in T2D populations and is useful for understanding glycemic behavior across the dose range. For the mechanism side, Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234–1247.e9 is the discovery paper and provides the preclinical pharmacology underpinning everything downstream.
Dose ranges documented in research. Clinical research has used weekly subcutaneous doses ranging from 0.5 mg up to 12 mg, titrated upward from a starting dose to mitigate GI tolerability issues common to the GLP-1 class. Published titration schedules typically begin at 2 mg and step up over 16–20 weeks. Research-context users should anchor their own experimental designs to the published titration schedules rather than extrapolate aggressively — GI tolerability is the dominant rate-limiting factor across all GLP-1-family compounds, and the glucagon arm of retatrutide does not appear to change this.
Storage, stability, and handling. Retatrutide in a prefilled pen is stable at 2–8 °C through the labeled expiry date. Once in use (first injection drawn), most GLP-1-class peptide solutions retain potency for 28 days at 2–8 °C or up to the period specified on the product page — the pen format's sealed cartridge is a significant stability advantage over open-vial reconstitution. Do not freeze; freeze-thaw cycles can disrupt peptide structure in solution and are grounds for discarding the unit. Protect from light and from repeated warming during handling. A pen that has been at room temperature for more than a few hours should be returned to refrigeration and its usable window recalculated.
What the COA should say. A batch-specific Certificate of Analysis for retatrutide should include (1) identity confirmation by HPLC-MS against the theoretical molecular mass of the peptide (retatrutide has a molecular weight of approximately 4731.4 Da for its engineered sequence), (2) purity by reverse-phase HPLC-UV at 214 nm with the main peak integrated and reported as area percent (Vivaprime's specification is ≥ 98.0%), (3) residual solvent profile per ICH Q3C covering acetonitrile, DMF, TFA, and other solvents used in synthesis, and (4) endotoxin quantitation by LAL reported in EU/mg. Every Vivaprime retatrutide batch ships with this documentation linked on the product page and on the order detail page for the specific batch received.
Why retatrutide is interesting right now. In a research context, retatrutide is the first compound where a single molecule engages all three validated incretin-family receptors, which makes it a tool for asking questions that previously required combinations of mono- and dual-agonists. For groups studying energy expenditure, substrate oxidation, or the GCGR-specific contribution to metabolic endpoints, retatrutide is a cleaner experimental tool than the alternative of dosing a separate glucagon analog alongside tirzepatide. The compound's pharmacokinetic profile (weekly dosing, predictable titration) also makes longitudinal experimental designs tractable in a way that short-acting agents do not.
Research-use only. Vivaprime supplies retatrutide as research reference material for qualified researchers engaged in in-vitro laboratory work. Nothing on this page, including the published literature references above, constitutes a therapeutic, diagnostic, or consumption recommendation. Retatrutide has not been approved by the FDA for any therapeutic indication as of publication. Purchasers affirm the research-use agreement at checkout. For compliance context, see the Research use policy linked from the site footer.